Evidence map›Paper›PMID 38658942›Full record

ArticleBMC proceedings2024

Insights into treatment of complex Crohn's perianal fistulas.

Gregor Norčič, Nataša Smrekar, Srđan Marković, Goran Barišić, Gediminas Kiudelis, Henrikas Paužas, Tamás Molnár, Attila Szijarto, Zuzana Šerclová, Tina Roblek and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC proceedings, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 8 countries.

Gregor NorčičUniversity Medical Centre Ljubljana, Zaloška Cesta 2, Ljubljana, Slovenia.
Nataša SmrekarUniversity Medical Centre Ljubljana, Zaloška Cesta 2, Ljubljana, Slovenia.
Srđan MarkovićClinical Hospital Centre Zvezdara, Preševska 31, Belgrade, Serbia.
Goran BarišićUniversity Clinical Centre of Serbia, Pasterova 2, Belgrade, Serbia.
Gediminas KiudelisLithuanian University of Health Sciences Kaunas Clinics, Eivenių G. 2, Kaunas, Lithuania.
Henrikas PaužasLithuanian University of Health Sciences Kaunas Clinics, Eivenių G. 2, Kaunas, Lithuania.
Tamás MolnárUniversity of Szeged, Dugonics Tér 13, Szeged, Hungary.
Attila SzijartoSemmelweis University, Üllői Út 26, Budapest, Hungary.
Zuzana ŠerclováMilitary University Hospital, U Vojenské Nemocnice 1200, Prague, Czechia.
Tina RoblekTakeda Pharmaceuticals, d.o.o., Bleiweisova Cesta 30, Ljubljana, Slovenia.
Viktor UršičTakeda Pharmaceuticals, d.o.o., Bleiweisova Cesta 30, Ljubljana, Slovenia.
Ian WhiteBeilinson Hospital, Rabin Medical Center, Ze'ev Jabotinsky Street 39, Petah Tikva, Israel. ian.white@clalit.org.il.
Lithuanian University of Health Sciences · LTLjubljana University Medical Centre · SITakeda (Japan) · JPKliničko Bolnički Centar Zvezdara · RSMilitary University Hospital Prague · CZSemmelweis University · HUTel Aviv University · ILUniversity Clinical Centre · PLUniversity of Szeged · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Complex perianal fistula is a common complication of Crohn's disease (CD) which leads to negative impact on patient's quality of life. Successful management of the disease requires a multidisciplinary approach, including a gastroenterologist and a colorectal surgeon, applying combined surgical and medical therapy. One of frequently practiced surgical procedures is seton placement in the fistula tract, which is used to control perianal sepsis and drain the fistula, while preventing recurrent abscess formation.Darvadstrocel, a suspension of expanded, allogeneic, adipose-derived, mesenchymal stem cells, is safe and effective for treatment-refractory complex perianal fistulas in patients with Crohn's disease. Following approval of darvadstrocel, the INSPIRE registry is being conducted in order to evaluate long-term safety and effectiveness of the drug on a large, heterogenous population.An online expert meeting was held from March 20 to March 30, 2023, which provided relevant insights into the decision-making process regarding seton use and obtained feedback on the first experiences with darvadstrocel. The aim of this article is to present the perspectives from gastroenterologists and colorectal surgeons practicing in Czechia, Hungary, Israel, Lithuania, Serbia, and Slovenia in topics such as diagnosis and treatment options for patients with complex Crohn's perianal fistulas (CPF), specifically focusing on the use of setons and darvadstrocel.During this virtual session, unavailability of comprehensive data on safety and efficacy of available treatment procedures was emphasized as an important obstacle towards development of standardized recommendations and improvement of outcomes in treatment of (CPF). Furthermore, achieving consensus in seton use, duration of its placement, and frequency of change is recognized as one of CPF treatments major challenges. Despite these issues, it is important to promote better understanding and treatment of complex perianal fistulas in order to improve the quality of life of those affected by this condition.

Indexed as

Crohn's DiseaseDarvadstrocel TherapyLong-term Safety EvaluationMultidisciplinary ManagementPerianal FistulasSurgical ProceduresTreatment Challenges

Identifiers

PMID38658942
PMCPMC11044286
OpenAlexW4395067153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.